{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:02:27Z","timestamp":1788580947264,"version":"build-2803163510"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Stroke"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Understanding the neurobiological underpinnings between established multimodal dementia risk factors and noninvasive blood-based biomarkers may lead to greater precision and earlier identification of older adults at risk of accelerated decline and dementia. We examined whether key vascular and genetic risk impact the association between cerebral amyloid burden and plasma a\u03b2 (amyloid \u03b2) 42\/40 in nondemented older adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      We used nondemented older adults from the UCD-ADRC (University of California, Davis-Alzheimer\u2019s Disease Research Center) study (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =96) and Alzheimer\u2019s Disease Neuroimaging Initiative (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =104). Alzheimer\u2019s Disease Neuroimaging Initiative was examined as confirmatory study cohort. We followed a cross-sectional design and examined linear regression followed by mediation analyses. Vascular risk score was obtained as the sum of hypertension, diabetes, hyperlipidemia, coronary artery disease, and cerebrovascular disease.\n                      <jats:italic toggle=\"yes\">Apolipoprotein E<\/jats:italic>\n                      (\n                      <jats:italic toggle=\"yes\">APOE<\/jats:italic>\n                      ) \u03b54+ risk was genotyped, and plasma a\u03b242 and a\u03b240 were assayed. Cerebral amyloid burden was quantified using Florbetapir-PET scans. Baseline age was included as a covariate in all models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Vascular risk significantly predicted cerebral amyloid burden in Alzheimer\u2019s Disease Neuroimaging Initiative but not in the UCD-ADRC cohort. Cerebral amyloid burden was associated with plasma a\u03b2 42\/40 in both cohorts. Higher vascular risk increased cerebral amyloid burden was indirectly associated with reduced plasma a\u03b2 42\/40 in Alzheimer\u2019s Disease Neuroimaging Initiative but not in UCD-ADRC cohort. However, when stratified by\n                      <jats:italic toggle=\"yes\">APOE<\/jats:italic>\n                      \u03b54+ risk, we consistently observed this indirect relationship only in\n                      <jats:italic toggle=\"yes\">APOE<\/jats:italic>\n                      \u03b54+ carriers across both cohorts.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Vascular risk is indirectly associated with the level of plasma a\u03b2 42\/40 via cerebral amyloid burden only in\n                      <jats:italic toggle=\"yes\">APOE<\/jats:italic>\n                      \u03b54+ carriers. Nondemented older adults with genetic vulnerability to dementia and accelerated decline may benefit from careful monitoring of vascular risk factors directly associated with cerebral amyloid burden and indirectly with plasma a\u03b2 42\/40.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/strokeaha.122.041854","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T05:00:51Z","timestamp":1680757251000},"page":"1227-1235","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Vascular Risk Predicts Plasma Amyloid \u03b2 42\/40 Through Cerebral Amyloid Burden in\n                    <i>Apolipoprotein E<\/i>\n                    \u03b54 Carriers"],"prefix":"10.1161","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4806-8939","authenticated-orcid":true,"given":"Shraddha","family":"Sapkota","sequence":"first","affiliation":[{"name":"Department of Neurology (S.S., E.F., S.E.T.F., C.D.), University of California, Davis."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Erickson","sequence":"additional","affiliation":[{"name":"Department of Neurology (S.S., E.F., S.E.T.F., C.D.), University of California, Davis."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9761-3131","authenticated-orcid":true,"given":"Evan","family":"Fletcher","sequence":"additional","affiliation":[{"name":"University of California, and Department of Pathology and Laboratory Medicine (K.E., L.-W.J.), University of California, Davis."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8969-3387","authenticated-orcid":true,"given":"Sarah E.","family":"Tomaszewski Farias","sequence":"additional","affiliation":[{"name":"Department of Neurology (S.S., E.F., S.E.T.F., C.D.), University of California, Davis."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-Way","family":"Jin","sequence":"additional","affiliation":[{"name":"University of California, and Department of Pathology and Laboratory Medicine (K.E., L.-W.J.), University of California, Davis."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1914-2693","authenticated-orcid":true,"given":"Charles","family":"DeCarli","sequence":"additional","affiliation":[{"name":"Department of Neurology (S.S., E.F., S.E.T.F., C.D.), University of California, Davis."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Alzheimer\u2019s Disease Neuroimaging Initiative*","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00361-6"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-307662"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01348-z"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2019.04.001"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008081"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-01899-w"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep26801"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05253-y"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0079-7"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.621023"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-210358"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20780"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.1123"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000435301.64776.37"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.1342"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.650679"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-215068"},{"key":"e_1_3_3_19_2","first-page":"1","article-title":"Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer\u2019s disease.","volume":"11","author":"Lin SY","year":"2019","unstructured":"Lin, SY, Lin, KJ, Lin, PC, Huang, CC, Chang, CC, Lee, YC, Hsiao, IT, Yen, TC, Huang, WS, Yang, BH, et al. Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther. 2019;11:1\u201310. https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-019-0566-0","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0b013e3181c1ee01"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.wad.0000213865.09806.92"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0b013e318191c7dd"},{"key":"e_1_3_3_23_2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/jamasurg.2021.0528","article-title":"STROBE reporting guidelines for observational studies.","volume":"156","author":"Ghaferi AA","year":"2021","unstructured":"Ghaferi, AA, Schwartz, TA, Pawlik, TM. STROBE reporting guidelines for observational studies. JAMA Surg. 2021;156:577\u2013578. https:\/\/jamanetwork.com\/journals\/jamasurgery\/fullarticle\/2778474","journal-title":"JAMA Surg"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12215"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-011-0861-8"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010531"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2010.03.003"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2015.05.009"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30412-9"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-180965"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.284"},{"key":"e_1_3_3_32_2","volume-title":"Mplus user\u2019s guide","author":"Muth\u00e9n L","year":"1998","unstructured":"Muth\u00e9n, L, Muth\u00e9n, B. Mplus user\u2019s guide. 1998."},{"key":"e_1_3_3_33_2","unstructured":"Muth\u00e9n B Asparouhov T Sobel M. Applications of causally defined direct and indirect effects in mediation analysis using SEM in Mplus. Economics. 2011. http:\/\/www.statmodel2.com\/download\/causalmediation.pdf"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1037\/\/0022-3514.51.6.1173"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadm.2019.05.007"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab163"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2015.00115"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.5390"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.178962"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012775"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0228-7"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-016-1427-y"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2018.00180"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/726197"},{"key":"e_1_3_3_45_2","first-page":"1","article-title":"Effect of APOE \u03b54 genotype on amyloid-\u03b2 and tau accumulation in Alzheimer\u2019s disease.","volume":"12","author":"Baek MS","year":"2020","unstructured":"Baek, MS, Cho, H, Lee, HS, Lee, JH, Ryu, YH, Lyoo, CH. Effect of APOE \u03b54 genotype on amyloid-\u03b2 and tau accumulation in Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther. 2020;12:1\u201312. https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-020-00710-6","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182167147"},{"key":"e_1_3_3_47_2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/NEN.0b013e31816a0dc8","article-title":"Apolipoprotein E, Amyloid-\u03b2, and Blood-brain barrier permeability in alzheimer disease.","volume":"67","author":"Donahue JE","year":"2008","unstructured":"Donahue, JE, Johanson, CE. Apolipoprotein E, Amyloid-\u03b2, and Blood-brain barrier permeability in alzheimer disease. J Neuropathol Exp Neurol. 2008;67:261\u2013270. https:\/\/academic.oup.com\/jnen\/article\/67\/4\/261\/2916878","journal-title":"J Neuropathol Exp Neurol"},{"key":"e_1_3_3_48_2","doi-asserted-by":"crossref","unstructured":"Castellano JM Kim J Stewart FR Jiang H DeMattos RB Patterson BW Fagan AM Morris JC Mawuenyega KG Cruchaga C et al. Human apoE isoforms differentially regulate brain amyloid-\u03b2 peptide clearance. Sci Transl Med. 2011;3:89ra57. http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=3192364&tool=pmcentrez&rendertype=abstract","DOI":"10.1126\/scitranslmed.3002156"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2013.01.007"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2015.08.003"},{"key":"e_1_3_3_51_2","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019.","volume":"7","author":"Nichols E","year":"2022","unstructured":"Nichols, E, Steinmetz, JD, Vollset, SE, Fukutaki, K, Chalek, J, Abd-Allah, F, Abdoli, A, Abualhasan, A, Abu-Gharbieh, E, Akram, TT, et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Heal. 2022;7:e105\u2013e125. http:\/\/www.thelancet.com\/article\/S2468266721002498\/fulltext","journal-title":"Lancet Public Heal"}],"container-title":["Stroke"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/STROKEAHA.122.041854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:36:32Z","timestamp":1777491392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/STROKEAHA.122.041854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1161\/STROKEAHA.122.041854"],"URL":"https:\/\/doi.org\/10.1161\/strokeaha.122.041854","relation":{},"ISSN":["0039-2499","1524-4628"],"issn-type":[{"value":"0039-2499","type":"print"},{"value":"1524-4628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"2022-11-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}